Related Experiment Video

Updated: Aug 22, 2026

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader
07:13

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader

Published on: May 24, 2024

Pathophysiological role of proteasome-dependent proteolytic pathway in endothelin-1-related cardiovascular diseases

M Takaoka1, M Ohkita, Y Matsumura

  • 1Department of Pharmacology, Osaka University of Pharmaceutical Sciences, 4-20-1 Nasahara, Takatsuki, Osaka, Japan.

Current Vascular Pharmacology
|August 24, 2004
PubMed

Insights

Proteasome inhibitors prevent hypertension and kidney damage by reducing endothelin-1 (ET-1) levels. This pathway involves nuclear factor-kappaB (NF-kappaB) activation, suggesting proteasome inhibitors as a novel cardiovascular disease treatment.

Area of Science:

  • Cardiovascular Pathophysiology
  • Molecular Biology
  • Proteasome Function

Background:

  • The role of proteasome-dependent pathways in cardiovascular diseases remains largely unknown.
  • Proteasomes are crucial for protein degradation, influencing cellular processes like cell cycle control and gene transcription.

Purpose of the Study:

  • To investigate the pathophysiological role of proteasome pathways in cardiovascular diseases.
  • To explore the therapeutic potential of proteasome inhibitors in hypertension and acute renal failure models.

Main Methods:

  • Utilized deoxycorticosterone acetate (DOCA)-salt-induced hypertension and ischemic acute renal failure (ARF) animal models.
  • Administered proteasome inhibitors and measured endothelin-1 (ET-1) levels.
  • Assessed nuclear factor-kappaB (NF-kappaB) activation in cultured vascular endothelial cells.

Main Results:

  • Proteasome inhibitors prevented DOCA-salt-induced hypertension and hypertrophy, and ischemic ARF.
  • Beneficial effects correlated with decreased ET-1 content in the aorta and kidney.
  • Inhibition of NF-kappaB activation was linked to reduced ET-1 gene transcription and mRNA expression.

Conclusions:

  • Proteasome-dependent pathways play a critical role in the pathogenesis of ET-1-related cardiovascular diseases, likely via NF-kappaB activation.
  • Proteasome inhibitors represent a potential novel therapeutic strategy for cardiovascular diseases.

More Related Videos

Molecular Analysis of Endothelial-mesenchymal Transition Induced by Transforming Growth Factor-β Signaling07:49

Molecular Analysis of Endothelial-mesenchymal Transition Induced by Transforming Growth Factor-β Signaling

Published on: August 3, 2018

Related Concept Videos

The Proteasome01:13

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin...
The Proteasome02:18

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...